

GP 1642

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on March 12, 2001

TOWNSEND and TOWNSEND and CREW LLP  
By: *[Signature]*

PATENT  
Attorney Docket No.: 17634-000512US  
Client Reference No.: E-142-96/6

*#14*  
*3/27/01*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brian R. Murphy, et al.

Application No.: 09/444,067

Filed: November 19, 1999

For: PRODUCTION OF ATTENUATED  
RESPIRATORY SYNCYTIAL VIRUS  
VACCINES FROM CLONED  
NUCLEOTIDE SEQUENCES

Examiner: B. Brumback

Art Unit: 1642

RECEIVED

MAR 20 2001

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION  
REQUIREMENT AND SPECIES  
ELECTION REQUIREMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This is in response to the Restriction Requirement mailed January 10, 2001, which set forth the following groups of claims:

I. Claims 63-69, 88-95, 108-114, 119-122, 128-138, 147-150, and 156-161, drawn to recombinant respiratory syncytial virus (RSV) with a gene deletion, classified in class 424, subclass 211.1.

II. Claims 70-78, and 139-145, drawn to recombinant RSV with a modification of one or more nucleotides that modulate gene expression (knock-out mutants), classified in class 424, subclass 211.1.

III. Claims 63, 96-107, 115-118, 128, 131, and 151-155, drawn to chimeric RSV, classified in class 424, subclass 199.1.